Association of Age with Risk of Adverse Pathological Findings in Men Undergoing Delayed Radical Prostatectomy Following Active Surveillance.

To determine if older men with Gleason grade group (GG) 1 prostate cancer have a higher risk of having adverse pathology at radical prostatectomy after initially being managed with active surveillance (AS).

A total of 365 patients with GG1 prostate cancer initially managed with AS followed by delayed radical prostatectomy were identified. The primary outcome was adverse pathology after delayed radical prostatectomy in the men that were <65 years versus men ≥65 years at the initiation of AS. Adverse pathology was defined as GG≥3 or pT3 or pN1. Multivariable Cox proportional hazards regression models were used to calculate risk of adverse pathological findings at radical prostatectomy by age group.

At diagnosis, there were no significant differences in median prostate specific antigen density, percent positive biopsy cores, multiparametric magnetic resonance imaging (mpMRI) results or composite genomic classifier scores (derived from three commercially available genomic tests) between the two age groups. Men ≥65 years had more adverse pathology at radical prostatectomy (59.2% vs 44.1%, p<0.01) and lower rates of biopsy upgrade-free survival and adverse pathology-free survival (log-rank p<0.01). On multivariable analysis age ≥65 years (Hazard Ratio (HR) 2.21, 95% Confidence Interval (CI) 1.57, 3.12) was associated with adverse pathology at radical prostatectomy. In separate multivariable analyses done for each age group, mpMRI (HR 3.33, 95% CI 1.01, 10.95) was predictor of adverse pathology in the group ≥65 years.

Older patients might require closer monitoring on AS and additional testing such as mpMRI might improve their risk stratification.

Urology. 2021 Jun 09 [Epub ahead of print]

Claire M de la Calle, Kevin Shee, Carissa E Chu, Janet E Cowan, Hao G Nguyen, Peter R Carroll

Department of Urology, UCSF - Helen Diller Comprehensive Cancer Center, University of California, San Francisco, CA, USA. Electronic address: ., Department of Urology, UCSF - Helen Diller Comprehensive Cancer Center, University of California, San Francisco, CA, USA., Department of Urology, UCSF - Helen Diller Comprehensive Cancer Center, University of California, San Francisco, CA, USA. Electronic address: .

Go Beyond the Abstract and Read a Commentary by the Author